NY-CURIA
Curia, formerly AMRI, a leading contract research, development and manufacturing organization, today announced it has entered into a definitive agreement to acquire Integrity Bio, Inc., a privately held formulation and fill-finish organization headquartered in Camarillo, California.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210713005391/en/
Integrity Bio is known in the biopharmaceutical industry as experts in hard-to-formulate biologics and fill-finish of unique therapies in preclinical and clinical development. In a typical year, the organization formulates more than 60 large molecules including proteins, antibodies, lipid nanoparticles, peptides and vaccines in liquid and lyophilized form. The company recently expanded its facilities to include a second state-of-the-art fill-finish line, which more than doubled its manufacturing capacity. Integrity Bio’s customers range from global Fortune 500 companies to small virtual startups.
Integrity Bio’s biologic capabilities are complementary with Curia’s existing business and will enable Curia to expand its ability to meet customers’ needs. Curia currently provides customers with integrated solutions from formulation development through fill-finish commercial manufacturing across three center-of-excellence facilities in Albuquerque, New Mexico; Burlington, Massachusetts and Glasgow, Scotland.
“Curia has decades of experience in managing complexity from R&D through manufacturing,” said Curia Chairman and CEO John Ratliff. “I’m looking forward to welcoming the Integrity Bio team. The addition of Integrity Bio is a great fit with our growth strategy and our existing expertise, enhancing our biologics drug product formulation development as well as our fill-finish network. Integrity Bio also adds West Coast coverage to Curia’s East Coast and European capabilities. Together, we can make an even bigger impact on patients’ lives.”
“We are very excited about this transaction; the strategic fit is sound,” said Michael Reilly, CEO of Integrity Bio. “As part of Curia, we can now offer our customers not only world-class formulation and fill-finish but also world-class commercial manufacturing.”
The transaction, which is subject to standard and customary closing conditions, is expected to close in the third quarter. Terms of the agreement have not been disclosed.
About Curia
Curia, formerly AMRI, is a leading contract research, development and manufacturing organization providing products and services from R&D through commercial manufacturing to pharmaceutical and biopharmaceutical customers. Curia’s 3,100 employees at 21 locations across the U.S., Europe and Asia help its customers advance from curiosity to cure. Learn more at CuriaGlobal.com .
About Integrity Bio
Integrity Bio is a privately owned company focused on providing large molecule formulation and fill/finish services to the biotech and pharmaceutical industries. The organization is known for overcoming challenges associated with biologic formulations and for accommodating unique manufacturing requirements for preclinical and clinical development. For more information, please visit IntegrityBio.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210713005391/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Tahoe Therapeutics Selects Parse Biosciences’ GigaLab to Generate 300 Million Single Cell Profiles for Large-Scale Perturbation Atlas11.12.2025 14:00:00 CET | Press release
Parse’s GigaLab to provide industry leading, large-scale, single cell services to support Tahoe’s development of foundational biological datasets Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced that Tahoe Therapeutics has selected Parse’s GigaLab to generate data for its upcoming 300M cell project. Tahoe will use its proprietary Mosaic technology to generate samples consisting of 300M cells from large arrays of disease models, genetically or chemically perturbed. Under this agreement, Parse will apply its Evercode™ chemistry and high-throughput automation to these samples to deliver the largest perturbation-focused single cell dataset ever produced. Parse’s GigaLab, designed specifically for million- to hundred-million-cell projects, has rapidly become an industry benchmark for large-scale, reproducible single cell data generation. The facility integrates high-capacity liquid handling, standardized workflows, and end-to
Xsight Labs X2 Switch to Enable Next-Generation Starlink Satellites and Deliver Gigabit Connectivity11.12.2025 14:00:00 CET | Press release
High-bandwidth, ultra-low-power chip is leveraged for Starlink V3 satellites and future next-generation communication systems. News Highlights: Xsight’s X2 switch enables Starlink V3 satellite Delivers the performance required for rapid data processing, stable telemetry, and real-time operational responsiveness for Starlink X2’s flexible, programmable architecture adapts seamlessly to diverse orbital and ground-based networking workloads Xsight Labs, an innovator in high-performance connectivity silicon, today announced that Starlink, the world’s most advanced satellite constellation in low-Earth orbit, delivering broadband, will leverage the Xsight X2 Programmable Ethernet switch to serve as the high-speed networking core for its next-generation Starlink V3 satellites. Each V3 Starlink satellite is designed to deliver more than 1 terabit per second (Tbps) of fronthaul throughput, more than 10× the capacity delivered by Starlink V2 Mini satellites, and about 160 gigabits per second (Gb
Payments Leaders Unprepared for 2026 Disruption, Warns ACI Worldwide11.12.2025 13:00:00 CET | Press release
ACI’s Top Ten Payments Predictions for 2026 urges payments leaders to act amid structural shifts in global payments Most global payments leaders lack a clear roadmap to navigate the seismic changes coming in 2026 , according to the latest Top Ten Payments Predictions from ACI Worldwide (NASDAQ: ACIW), an original innovator in global payments technology. With AI-driven intelligence, next-gen authentication, new regulatory frameworks, and soaring demand for instant, embedded, and secure payments, the industry is entering an era of structural disruption. However, ACI’s recent report Payments in Transition: Leadership in an era of transformation reveals that only 36% of payments executives have a clear long-term modernization roadmap, leaving many without a strategic vision for transformation. “In 2026, payments disruption won’t be incremental—it will be structural,” said Philip Bruno, Chief Strategy and Growth Officer at ACI Worldwide. “Real-time is now the baseline, digital assets are en
Andersen Global styrker sine vurderingskapaciteter i Asien og Stillehavsområdet med ETC11.12.2025 12:29:00 CET | Pressemeddelelse
Andersen Global fortsætter med at udvide sin tilstedeværelse i Asien og Stillehavsområdet gennem en samarbejdsaftale med Edmund Tie & Company (ETC), et full-service ejendomsrådgivningsfirma med hovedsæde i Singapore. ETC blev stiftet i 1995 og leverer vurderings- og rådgivningsydelser på tværs af ejendommens livscyklus, herunder lovpligtig og selskabsrelateret vurdering, investeringsrådgivning, feasibility-analyser og rådgivning om ejendomsskat. Med aktiviteter i Singapore, Malaysia og Thailand kombinerer ETC dybdegående regional viden med internationale standarder for at støtte udviklere, investorer, private og statslige fonde, selskaber, REIT'er samt ejere og lejere. Firmaet er kendt for sin forskningsbaserede tilgang og integrerede servicemodel og hjælper kunder med at navigere i komplekse lovgivninger og optimere værdien af deres aktiver. "Vores styrke ligger ikke kun i den tekniske udførelse, men i at hjælpe kunder med at se det fulde billede – at forbinde markedssignaler, lovgivn
AB InBev and International Cricket Council Announce Landmark Global Partnership11.12.2025 10:31:00 CET | Press release
World’s Leading Brewer becomes the Official Beer Partner of the ICC The International Cricket Council (ICC) announced AB InBev (Euronext: ABI) (NYSE: BUD) (MEXBOL: ANB) (JSE: ANH), the world’s leading brewer, will become the Official Beer Partner for all major ICC tournaments starting in 2026. The partnership will be led by Budweiser 0.0, Budweiser’s no-alcohol beer in India, with other ABI mega brands activating in Europe and Africa. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251211250826/en/ AB InBev and ICC announce global partnership From attending a match live in-stadium to watching one at a bar or pub with friends, with a lower alcohol-by-volume (ABV) and no-alcohol options like Budweiser 0.0, beer is the natural choice to enjoy responsibly. Through this partnership with the ICC, AB InBev will create more moments of cheers, choice and celebration for cricket fans of legal drinking age all over the world. ICC CEO, S
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom